Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?

article OA: green CC0
AI-generated summary by gemini-2.5-flash-lite, 2026-06-07

Loss of BAF250a expression was observed in some endometriotic lesions, particularly endometriomas, suggesting a potential role in malignant transformation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text

This paper investigated whether loss of ARID1A/BAF250a protein expression could serve as a biomarker for risk of carcinogenic transformation in endometriosis, motivated by the frequent ARID1A mutations reported in endometriosis-associated ovarian clear cell and endometrioid carcinomas. The study examined ARID1A/BAF250a expression patterns in endometriosis tissue using a biomarker approach, aiming to link early molecular changes in endometriosis to later malignant transformation. The key finding, as framed by the paper’s premise, is that ARID1A/BAF250a expression loss occurs in endometriosis in a way that supports its role as an indicator of transformation risk, though the paper itself emphasizes the biomarker context and the transformation hypothesis rather than proving progression causality. This paper is centrally about endometriosis — it tests loss of ARID1A/BAF250a expression in endometriosis as a biomarker for carcinogenic transformation risk.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Mutations of the tumor-suppressor gene ARID1A result in the loss of protein expression of the BRG-associated factor 250a (BAF250a), a large subunit of transcription-regulating Human SWI/SNF complexes, which have an important role in the control of cell proliferation and tumor suppression. ARID1A mutations are particularly frequent in endometriosis-associated ovarian clear cell and endometrioid carcinomas, and were recently described as a possible key mechanism and early step in the transformation of endometriosis into cancer. Here, we examined the immunohistochemical expression pattern of BAF250a in a tissue microarray including 74 endometriosis and 30 endometrium samples. Ovarian cancer samples (n=136) served as a control. Epithelial BAF250a expression was assessable in 90/104 (87%) and stromal BAF250a expression in 95/104 (91%) of the endometriosis, and endometrium cases due to lack of adequate tissue in some spots. Complete lack of BAF250a expression was observed in three endometriomas (n=3/20, 15%) and one deep-infiltrating endometriosis sample (n=1/22, 5%), but in none of the peritoneal endometriosis (n=0/16) and eutopic endometrium samples (n=0/30). A comparison of the mean immunoreactivity scores revealed a significantly lower expression rate of BAF250a in endometriomas compared with normal endometrium (P<0.0005), as well as peritoneal (P=0.003) and deep-infiltrating endometriosis (P=0.02). Our data demonstrates that a complete loss of BAF250a expression is observable in some endometriotic lesions, especially in endometriomas. In addition, we report that a partial loss of BAF250a expression is occurring in the form of cell clusters indicating a clonal loss of BAF250a expression in these cells. The loss of expression of the tumor-suppressor protein BAF250a in some endometriomas possibly indicates a risk of malignant transformation in these cases, which could be of importance in the determination of individual treatment strategies. However, its role and value as a prognostic parameter in endometriosis needs to be further studied.Modern Pathology advance online publication, 3 February 2012; doi:10.1038/modpathol.2011.217.
Full text 1,963 characters · extracted from oa-html · 2 sections · click to expand

Abstract

Abstract

Abstract

Mutations of the tumor-suppressor gene ARID1A result in the loss of protein expression of the BRG-associated factor 250a (BAF250a), a large subunit of transcription-regulating Human SWI/SNF complexes, which have an important role in the control of cell proliferation and tumor suppression. ARID1A mutations are particularly frequent in endometriosis-associated ovarian clear cell and endometrioid carcinomas, and were recently described as a possible key mechanism and early step in the transformation of endometriosis into cancer. Here, we Metrics Downloads Views Additional indexing Creators (Authors) Volume Volume Volume Number Number Number Page range/Item number Page range/Item number Page range/Item number Page end Page end Page end Item Type Item Type Item Type Dewey Decimal Classifikation Dewey Decimal Classifikation Dewey Decimal Classifikation Language Language Language Publication date Publication date Publication date Date available Date available Date available ISSN or e-ISSN ISSN or e-ISSN ISSN or e-ISSN OA Status OA Status OA Status Publisher DOI Metrics Downloads Views Citations Samartzis, E. P., Samartzis, N., Noske, A., Fedier, A., Caduff, R., Dedes, K. J., Fink, D., & Imesch, P. (2012). Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation? Modern Pathology, 25, 885–892. https://doi.org/10.1038/modpathol.2011.217

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-10T11:03:26.981315+00:00
License: CC0 · commercial use OK